XML 63 R48.htm IDEA: XBRL DOCUMENT v3.22.1
Fair Value of Financial Instruments - Narrative (Details)
$ in Thousands
3 Months Ended
Feb. 20, 2020
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
Fair Value, Option, Quantitative Disclosures [Line Items]        
Company acquired right to receive certain future milestone   $ 208,880 $ 92,509  
Contingent consideration liabilities   $ 104,200   $ 86,200
Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Royalty percentage   0.05    
Aggregate cash payments percentage 40.00%      
Potential payments, high $ 100,000 $ 85,000    
Progenics | Current Liabilities        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities   83,300    
Progenics | Noncurrent Liabilities        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities   8,400    
Progenics | Cash Payments 2022        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities 100,000      
Progenics | Cash Payments 2023        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Contingent consideration liabilities $ 150,000      
Progenics | Net Sales Targets For Azedra        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   70,000    
Progenics | 1095 commercialization milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payments, high   5,000    
Progenics | 1404 Commercialization Milestone        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Potential payment not reasonably possible   10,000    
Royalty | Progenics        
Fair Value, Option, Quantitative Disclosures [Line Items]        
Company acquired right to receive certain future milestone   $ 5,000